Literature DB >> 2732139

In-vitro activity of the penem, FCE 22101, and tentative interpretive criteria for disc susceptibility tests.

A L Barry1, R N Jones, C Thornsberry.   

Abstract

The in-vitro activities of two penems (FCE 22101 and SCH 34343) were compared to those of a carbapenem (imipenem), a monobactam (aztreonam) and three cephalosporins (cefoperazone, ceftazidime, and cefotaxime). FCE 22101 displayed a broad spectrum of antibacterial activity against both Gram-negative and Gram-positive pathogens, including anaerobic bacteria. Imipenem and aztreonam, however, were a little more potent against susceptible species. FCE 22101 was bactericidal against 14 of 18 isolates tested; one strain each of Enterobacter cloacae, Staphylococcus aureus (methicillin sensitive), Staph. aureus (methicillin resistant) and Streptococcus faecalis were not killed by FCE 22101. For disc diffusion tests, a 10 micrograms FCE 22101 disc is tentatively recommended with zones of less than or equal to 13 mm for resistant (MIC greater than 8.0 mg/l) and greater than or equal to 17 mm for susceptible (MIC less than or equal to 4.0 mg/l). Those criteria need to be reevaluated when additional pharmacokinetic information and clinical experience have been gathered.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2732139     DOI: 10.1093/jac/23.suppl_c.17

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  2 in total

1.  Comparative antimicrobial activities of the penem WY-49605 (SUN5555) against recent clinical isolates from five U.S. medical centers.

Authors:  D Sewell; A Barry; S Allen; P Fuchs; J McLaughlin; M Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

2.  Clinical and bacteriological efficacy and tolerability of FCE 22891 in patients with exacerbations of chronic obstructive pulmonary disease.

Authors:  W G Boersma; S M Puister; R van Altena; H G de Vries-Hospers; M Molinari; G H Koëter
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.